Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

BioDelivery Sciences International, Inc. has filed its Annual Report with the U.S. Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2009. Such Form 10-K is available on the SEC’s website at www.sec.gov.

20 Mar 2010

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease following four cycles of standard platinum-based first-line chemotherapy.

19 Mar 2010

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting.

19 Mar 2010

Feelings of guilt and shame haunt mothers with eating difficulties

They would love to be perfect mothers. Instead, they feel ashamed and inadequate, and fearful that their children might inherit their eating difficulties.

18 Mar 2010

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), as assessed by independent radiologist review.

17 Mar 2010

Stomach wrap operations more effective than acid suppression tablets in severe acid reflux treatment

Stomach wrap operations may be more effective than acid suppression tablets in the treatment of severe acid reflux, according to a new Cochrane Systematic Review. The study shows a more pronounced improvement in symptoms shortly after surgery than with drug treatment.

17 Mar 2010

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

An interventional radiology treatment-the use of intra-arterial yttrium-90 microspheres for liver cancer (also known as hepatocellular carcinoma)-shows promise in prolonging life for many patients with this devastating condition, according to researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

Novel procedure opens door to new and future treatment for pancreatic cancer

Pancreatic cancer-known as the most fatal cancer with no known effective treatment-requires a radical new therapy. A promising approach may come in the form of tiny gold nanoparticles-loaded with a therapeutic agent to kill cancer-in a novel procedure called "nanoembolization," said researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

17 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2009.

15 Mar 2010

FDA looks into supply chain of black and red pepper as part of Salmonella Montevideo investigation

As part of the Salmonella Montevideo investigation, the Food and Drug Administration has been actively investigating the supply chain of black and red pepper supplied to Daniele International Inc., Pascoag, R.I.

15 Mar 2010

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.

12 Mar 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat- (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone.

12 Mar 2010

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

Traumatic brain injuries may lead to life-threatening complications

One of the most common questions I am asked after someone hits their head is, "How serious is this bump on my head and should I make an appointment?" Head injuries are the result of trauma to the scalp, skull or brain. Concussion, the most common type of traumatic brain injury (TBI), is an injury that occurs after a blow to the head and results in a temporary loss of consciousness.

12 Mar 2010

Abused children more likely to suffer abdominal pain and nausea

Children who have been abused psychologically, physically or sexually are more likely to suffer unexplained abdominal pain and nausea or vomiting than children who have not been abused, a study led by University of North Carolina at Chapel Hill researchers concludes.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

Pediatrics researchers identify major gene location responsible for EoE

Pediatrics researchers have identified the first major gene location responsible for a severe, often painful type of food allergy called eosinophilic esophagitis (EoE). In this disease, which may cause weight loss, vomiting, heartburn and swallowing difficulties, a patient may be unable to eat a wide variety of foods.

7 Mar 2010

Vomiting News and Research

Further Reading

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

Feelings of guilt and shame haunt mothers with eating difficulties

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Stomach wrap operations more effective than acid suppression tablets in severe acid reflux treatment

Liver cancer: Treatment with intra-arterial yttrium-90 microspheres promising

Novel procedure opens door to new and future treatment for pancreatic cancer

NDA for BYDUREON: FDA issues complete response letter

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

FDA looks into supply chain of black and red pepper as part of Salmonella Montevideo investigation

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

Genentech announces topline results from Phase III trial of Avastin

Traumatic brain injuries may lead to life-threatening complications

Abused children more likely to suffer abdominal pain and nausea

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

Pediatrics researchers identify major gene location responsible for EoE

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News